Who's Using Digital Breast Tomosynthesis?

Rapid adoption of breast tomosynthesis is more likely in better-educated, affluent socioeconomic regions.

Digital breast tomosynthesis (DBT), an FDA-approved adjunct to digital mammography (DM), produces three-dimensional images. Although DBT has a lower recall rate and higher sensitivity, its effect on cancer mortality in the context of the potential harms of overdiagnosis remains unclear. Investigators queried a claims database to evaluate rates of DBT adoption in a large, privately insured U.S. population from 2015 through 2017, when >9.6 million screening mammograms among women aged 40–74 were performed. Socioeconomic data were also obtained.

DBT use increased from 13% in 2015 to >43% in late 2017, becoming the predominant mode of screening. Adoption of DBT was slowest in the Southeast and faster in the Northeast and Northwest, as well as in…

Reviewing Author

Laila Samiian, MD, FACS

Disclosures

Leadership Positions in Professional SocietiesAssociation of Women Surgeons (Member, Publications Committee)

Laila Samiian, MD, FACS

Disclosures

Leadership Positions in Professional SocietiesAssociation of Women Surgeons (Member, Publications Committee)

Who's Using Digital Breast Tomosynthesis?

Topics

Reviewing Author